Myeloma cells suppress osteoblasts through sclerostin secretion

S. Colucci, G. Brunetti, A. Oranger, G. Mori, F. Sardone, G. Specchia, E. Rinaldi, P. Curci, V. Liso, G. Passeri, A. Zallone, R. Rizzi, M. Grano

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Wingless-type (Wnt) signaling through the secretion of Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2 and -3 has a key role in the decreased osteoblast (OB) activity associated with multiple myeloma (MM) bone disease. We provide evidence that another Wnt antagonist, sclerostin, an osteocyte-expressed negative regulator of bone formation, is expressed by myeloma cells, that is, human myeloma cell lines (HMCLs) and plasma cells (CD138+ cells) obtained from the bone marrow (BM) of a large number of MM patients with bone disease. We demonstrated that BM stromal cells (BMSCs), differentiated into OBs and co-cultured with HMCLs showed, compared with BMSCs alone, reduced expression of major osteoblastic-specific proteins, decreased mineralized nodule formation and attenuated the expression of members of the activator protein 1 transcription factor family (Fra-1, Fra-2 and Jun-D). Moreover, in the same co-culture system, the addition of neutralizing anti-sclerostin antibodies restored OB functions by inducing nuclear accumulation of β-catenin. We further demonstrated that the upregulation of receptor activator of nuclear factor κ-B ligand and the downregulation of osteoprotegerin in OBs were also sclerostin mediated. Our data indicated that sclerostin secretion by myeloma cells contribute to the suppression of bone formation in the osteolytic bone disease associated to MM.

Original languageEnglish
Article numbere27
JournalBlood Cancer Journal
Volume1
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Bone Diseases
Osteoblasts
Multiple Myeloma
Osteogenesis
RANK Ligand
Osteocytes
Cell Line
Catenins
Transcription Factor AP-1
Cytoplasmic and Nuclear Receptors
Stromal Cells
Coculture Techniques
Plasma Cells
Neutralizing Antibodies
Mesenchymal Stromal Cells
Bone Marrow Cells
Anti-Idiotypic Antibodies
Transcription Factors
Up-Regulation
Down-Regulation

Keywords

  • Multiple myeloma
  • Myeloma cells
  • Osteoblasts
  • Osteolysis
  • Sclerostin

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Colucci, S., Brunetti, G., Oranger, A., Mori, G., Sardone, F., Specchia, G., ... Grano, M. (2011). Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal, 1(6), [e27]. https://doi.org/10.1038/bcj.2011.22

Myeloma cells suppress osteoblasts through sclerostin secretion. / Colucci, S.; Brunetti, G.; Oranger, A.; Mori, G.; Sardone, F.; Specchia, G.; Rinaldi, E.; Curci, P.; Liso, V.; Passeri, G.; Zallone, A.; Rizzi, R.; Grano, M.

In: Blood Cancer Journal, Vol. 1, No. 6, e27, 06.2011.

Research output: Contribution to journalArticle

Colucci, S, Brunetti, G, Oranger, A, Mori, G, Sardone, F, Specchia, G, Rinaldi, E, Curci, P, Liso, V, Passeri, G, Zallone, A, Rizzi, R & Grano, M 2011, 'Myeloma cells suppress osteoblasts through sclerostin secretion', Blood Cancer Journal, vol. 1, no. 6, e27. https://doi.org/10.1038/bcj.2011.22
Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Specchia G et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal. 2011 Jun;1(6). e27. https://doi.org/10.1038/bcj.2011.22
Colucci, S. ; Brunetti, G. ; Oranger, A. ; Mori, G. ; Sardone, F. ; Specchia, G. ; Rinaldi, E. ; Curci, P. ; Liso, V. ; Passeri, G. ; Zallone, A. ; Rizzi, R. ; Grano, M. / Myeloma cells suppress osteoblasts through sclerostin secretion. In: Blood Cancer Journal. 2011 ; Vol. 1, No. 6.
@article{8f883696cbfc4492aae90c9964e5675c,
title = "Myeloma cells suppress osteoblasts through sclerostin secretion",
abstract = "Wingless-type (Wnt) signaling through the secretion of Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2 and -3 has a key role in the decreased osteoblast (OB) activity associated with multiple myeloma (MM) bone disease. We provide evidence that another Wnt antagonist, sclerostin, an osteocyte-expressed negative regulator of bone formation, is expressed by myeloma cells, that is, human myeloma cell lines (HMCLs) and plasma cells (CD138+ cells) obtained from the bone marrow (BM) of a large number of MM patients with bone disease. We demonstrated that BM stromal cells (BMSCs), differentiated into OBs and co-cultured with HMCLs showed, compared with BMSCs alone, reduced expression of major osteoblastic-specific proteins, decreased mineralized nodule formation and attenuated the expression of members of the activator protein 1 transcription factor family (Fra-1, Fra-2 and Jun-D). Moreover, in the same co-culture system, the addition of neutralizing anti-sclerostin antibodies restored OB functions by inducing nuclear accumulation of β-catenin. We further demonstrated that the upregulation of receptor activator of nuclear factor κ-B ligand and the downregulation of osteoprotegerin in OBs were also sclerostin mediated. Our data indicated that sclerostin secretion by myeloma cells contribute to the suppression of bone formation in the osteolytic bone disease associated to MM.",
keywords = "Multiple myeloma, Myeloma cells, Osteoblasts, Osteolysis, Sclerostin",
author = "S. Colucci and G. Brunetti and A. Oranger and G. Mori and F. Sardone and G. Specchia and E. Rinaldi and P. Curci and V. Liso and G. Passeri and A. Zallone and R. Rizzi and M. Grano",
year = "2011",
month = "6",
doi = "10.1038/bcj.2011.22",
language = "English",
volume = "1",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Myeloma cells suppress osteoblasts through sclerostin secretion

AU - Colucci, S.

AU - Brunetti, G.

AU - Oranger, A.

AU - Mori, G.

AU - Sardone, F.

AU - Specchia, G.

AU - Rinaldi, E.

AU - Curci, P.

AU - Liso, V.

AU - Passeri, G.

AU - Zallone, A.

AU - Rizzi, R.

AU - Grano, M.

PY - 2011/6

Y1 - 2011/6

N2 - Wingless-type (Wnt) signaling through the secretion of Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2 and -3 has a key role in the decreased osteoblast (OB) activity associated with multiple myeloma (MM) bone disease. We provide evidence that another Wnt antagonist, sclerostin, an osteocyte-expressed negative regulator of bone formation, is expressed by myeloma cells, that is, human myeloma cell lines (HMCLs) and plasma cells (CD138+ cells) obtained from the bone marrow (BM) of a large number of MM patients with bone disease. We demonstrated that BM stromal cells (BMSCs), differentiated into OBs and co-cultured with HMCLs showed, compared with BMSCs alone, reduced expression of major osteoblastic-specific proteins, decreased mineralized nodule formation and attenuated the expression of members of the activator protein 1 transcription factor family (Fra-1, Fra-2 and Jun-D). Moreover, in the same co-culture system, the addition of neutralizing anti-sclerostin antibodies restored OB functions by inducing nuclear accumulation of β-catenin. We further demonstrated that the upregulation of receptor activator of nuclear factor κ-B ligand and the downregulation of osteoprotegerin in OBs were also sclerostin mediated. Our data indicated that sclerostin secretion by myeloma cells contribute to the suppression of bone formation in the osteolytic bone disease associated to MM.

AB - Wingless-type (Wnt) signaling through the secretion of Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2 and -3 has a key role in the decreased osteoblast (OB) activity associated with multiple myeloma (MM) bone disease. We provide evidence that another Wnt antagonist, sclerostin, an osteocyte-expressed negative regulator of bone formation, is expressed by myeloma cells, that is, human myeloma cell lines (HMCLs) and plasma cells (CD138+ cells) obtained from the bone marrow (BM) of a large number of MM patients with bone disease. We demonstrated that BM stromal cells (BMSCs), differentiated into OBs and co-cultured with HMCLs showed, compared with BMSCs alone, reduced expression of major osteoblastic-specific proteins, decreased mineralized nodule formation and attenuated the expression of members of the activator protein 1 transcription factor family (Fra-1, Fra-2 and Jun-D). Moreover, in the same co-culture system, the addition of neutralizing anti-sclerostin antibodies restored OB functions by inducing nuclear accumulation of β-catenin. We further demonstrated that the upregulation of receptor activator of nuclear factor κ-B ligand and the downregulation of osteoprotegerin in OBs were also sclerostin mediated. Our data indicated that sclerostin secretion by myeloma cells contribute to the suppression of bone formation in the osteolytic bone disease associated to MM.

KW - Multiple myeloma

KW - Myeloma cells

KW - Osteoblasts

KW - Osteolysis

KW - Sclerostin

UR - http://www.scopus.com/inward/record.url?scp=84864062016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864062016&partnerID=8YFLogxK

U2 - 10.1038/bcj.2011.22

DO - 10.1038/bcj.2011.22

M3 - Article

C2 - 22829171

AN - SCOPUS:84864062016

VL - 1

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 6

M1 - e27

ER -